Will 14-3-3η Be a New Diagnostic and Prognostic Biomarker in Rheumatoid Arthritis? A Prospective Study of Its Utility in Early Diagnosis and Response to Treatment.
{"title":"Will 14-3-3<i>η</i> Be a New Diagnostic and Prognostic Biomarker in Rheumatoid Arthritis? A Prospective Study of Its Utility in Early Diagnosis and Response to Treatment.","authors":"Doaa Shawky Alashkar, Radwa Mostafa Elkhouly, Amira Yousef Abd Elnaby, Doaa Waseem Nada","doi":"10.1155/2022/1497748","DOIUrl":null,"url":null,"abstract":"<p><strong>Results: </strong>Serum14-3-3<i>η</i> levels were significantly higher in all RA patients than in controls (<i>P</i> < 0.001), its sensitivity was 86.7% and 88.3% in early and established RA patients with a significant difference with RF and ACCP at early disease, and the specificity was 96.7%. There was a significant reduction of 14-3-3<i>η</i> levels 6 months after treatment in the first group (<i>p</i>=0.004), and there was a significant positive correlation between serum 14-3-3<i>η</i> levels and parameters of disease activity and severity.</p><p><strong>Conclusion: </strong>14-3-3<i>η</i> could be a novel, potent, and efficacious diagnostic, and prognostic marker for RA with high sensitivity, that may become a new therapeutic target for RA.</p>","PeriodicalId":46314,"journal":{"name":"Autoimmune Diseases","volume":"2022 ","pages":"1497748"},"PeriodicalIF":1.7000,"publicationDate":"2022-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752307/pdf/","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Autoimmune Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2022/1497748","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 3
Abstract
Results: Serum14-3-3η levels were significantly higher in all RA patients than in controls (P < 0.001), its sensitivity was 86.7% and 88.3% in early and established RA patients with a significant difference with RF and ACCP at early disease, and the specificity was 96.7%. There was a significant reduction of 14-3-3η levels 6 months after treatment in the first group (p=0.004), and there was a significant positive correlation between serum 14-3-3η levels and parameters of disease activity and severity.
Conclusion: 14-3-3η could be a novel, potent, and efficacious diagnostic, and prognostic marker for RA with high sensitivity, that may become a new therapeutic target for RA.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
